Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection

PLoS One. 2014 Mar 11;9(3):e90977. doi: 10.1371/journal.pone.0090977. eCollection 2014.

Abstract

Interferon alpha (IFN-α) is commonly used for the treatment of chronic hepatitis B (CHB) patients. Many factors including viral genetics may determine the outcome of IFN-α therapy. In this study, we tested whether the expression of IFN-α directly in the liver inhibits HBV gene expression and replication using a HBV hydrodynamic injection (HI) mouse model. Two replication-competent clones from different HBV isolates that belonging to HBV genotype A and B based on a pAAV vector (pAAV-HBV-A and pAAV-HBV-B) were compared for their susceptibility to IFN-α. HBV clones were injected into mice either alone or in combination with a murine (m) IFN-α expression plasmid (pmIFN-α). HBsAg and HBeAg concentrations and HBV DNA levels in mice differed after injection of these two HBV clones. Co-application of pmIFN-α together with the two distinct isolates resulted in markedly different kinetics of decline of HBsAg, HBeAg, and HBV DNA levels in the mice. Immunohistochemical staining of liver sections with anti-HBc showed that mIFN-α application completely inhibited the expression of HBcAg in mice inoculated with pAAV-HBV-B, whereas the expression of HBcAg was only reduced in mice with pAAV-HBV-A. Consistently, mice injected with pAAV-HBV-B and pmIFN-α showed higher expression levels of the IFN-stimulated genes (ISGs) ISG15, OAS, PKR as well as proinflammatory cytokine IL-6 in the liver. In addition, expression levels of anti-inflammatory cytokine IL-10 was down-regulated significantly in liver of the mice injected with pAAV-HBV-B and pmIFN-α. Our data demonstrate that IFN-α exerts antiviral activity in HBV mouse model, but different HBV isolates may have diverse susceptibility to IFN-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / pharmacology*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Gene Expression
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Genotype
  • Hepatitis B / drug therapy
  • Hepatitis B / immunology
  • Hepatitis B / virology*
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B e Antigens / blood
  • Hepatitis B e Antigens / immunology
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B virus / isolation & purification
  • Humans
  • Interferon Regulatory Factors / genetics
  • Interferon Regulatory Factors / metabolism
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / pharmacokinetics
  • Interferon-alpha / pharmacology*
  • Liver / immunology
  • Liver / metabolism
  • Liver / pathology
  • Liver / virology
  • Male
  • Mice
  • Microbial Sensitivity Tests
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • Viral Load

Substances

  • Antiviral Agents
  • Cytokines
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Interferon Regulatory Factors
  • Interferon-alpha

Grants and funding

This work was supported by grants from National Major Science and Technology Project for Infectious Diseases of China (2012ZX10004503), State Major Basic Research Program of China (2005CB522901, 2007CB512804 and 2009CB522500), National Natural Science Foundation of China (30271170, 81201289) and International Science & Technology Cooperation Program of China (2011DFA31030) to D. Yang and grants of Deutsche Forschungsgemeinschaft (Transregio TRR60 and GK1045/2) to M. Lu. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.